MedTrace Logo

Erlotinib as Neoadjuvant Treatment in Patients With Stage â…¢A N2 NSCLC With Activating EGFR Mutation.

NCT01217619 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-09-12

No results posted yet for this study

Summary

This is a single arm, one center, phaseâ…¡ study evaluating efficacy and safety of erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage â…¢A N2 NSCLC with activating EGFR mutation in exon 19 or 21.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

erlotinib

erlotinib 150mg/d continuously for 56 days

Sponsors & Collaborators

  • Baohui Han

    lead OTHER

Principal Investigators

  • Baohui Han, MD · Shanghai Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-02
Primary Completion
2016-06-30
Completion
2016-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01217619 on ClinicalTrials.gov